Abbott reports first commercial Tendyne mitral valve implant in the U.S.

An Abbott (NYSE: ABT)+ official announced on social media that doctors completed the first commercial implant of Tendyne in the U.S.

Chris Waddell, Abbott’s U.S. VP for transcatheter aortic valve implantation (TAVI), posted the news on LinkedIn. It’s the latest milestone for Tendyne, a transcatheter mitral valve replacement (TMVR) system, after its FDA approval in May.

See full article: https://www.massdevice.com/abbott-first-us-tendyne-tmvr-implant/